Iron chelators as therapeutic agents against Pneumocystis carinii

G A Weinberg, G A Weinberg

Abstract

Iron plays a critical role in host-parasite interactions, and iron chelators have been demonstrated to serve as effective adjunct therapeutic agents against malaria. The effects of the parenteral iron chelator deferoxamine (DFO) on the growth of rat-derived Pneumocystis carinii were studied in a human fibroblast cell culture model and in two in vivo models of experimental infection. In addition, the effects of the investigational oral iron chelator CP20 and its 3-hydroxypyridin-4-one analogs CP51, CP94, and CP96 on the growth of P. carinii in vitro were assessed. DFO suppressed the growth of P. carinii in vitro in a dose-dependent manner, and daily injections of DFO markedly reduced the intensity of P. carinii infection in both mice and rats. Cell cultures treated with iron chelators that are administered orally to humans also showed substantial P. carinii growth inhibition. Reduction of P. carinii numbers after iron chelator therapy correlated with alterations in P. carinii morphology, as viewed by transmission electron microscopy. Since the use of current anti-P. carinii drugs is limited by toxicity or incomplete efficacy, or both, the role of iron chelation as adjunctive anti-P. carinii chemotherapy merits additional investigation.

References

    1. Lancet. 1993 Apr 24;341(8852):1088
    1. J Eukaryot Microbiol. 1993 Mar-Apr;40(2):188-95
    1. J Clin Invest. 1993 May;91(5):1979-86
    1. Am J Hematol. 1993 Apr;42(4):340-9
    1. Lancet. 1993 Jun 5;341(8858):1479-80
    1. Lancet. 1993 Jun 5;341(8858):1480
    1. J Clin Microbiol. 1993 Jun;31(6):1659-62
    1. J Med Chem. 1993 Aug 20;36(17):2448-58
    1. Microbiol Rev. 1978 Mar;42(1):45-66
    1. Br J Haematol. 1979 Aug;42(4):547-55
    1. Am J Trop Med Hyg. 1982 Sep;31(5):919-22
    1. Rev Infect Dis. 1983 Sep-Oct;5 Suppl 4:S759-77
    1. Physiol Rev. 1984 Jan;64(1):65-102
    1. Infect Immun. 1985 Mar;47(3):774-9
    1. Diagn Microbiol Infect Dis. 1985 Sep;3(5):381-7
    1. Exp Parasitol. 1985 Oct;60(2):171-4
    1. Lancet. 1987 Jun 6;1(8545):1294-5
    1. Crit Rev Microbiol. 1988;16(2):81-111
    1. Baillieres Clin Haematol. 1989 Apr;2(2):257-92
    1. Blood. 1989 Nov 1;74(6):2166-71
    1. Q Rev Biol. 1989 Sep;64(3):261-90
    1. Semin Hematol. 1990 Apr;27(2):95-100
    1. Blood. 1990 Sep 15;76(6):1250-5
    1. Br J Haematol. 1990 Aug;75(4):598-602
    1. Acta Paediatr Scand Suppl. 1989;361:53-62
    1. Antimicrob Agents Chemother. 1990 Sep;34(9):1833-5
    1. Drug Metab Rev. 1990;22(5):531-79
    1. Antimicrob Agents Chemother. 1991 Feb;35(2):277-82
    1. Clin Microbiol Rev. 1991 Apr;4(2):137-49
    1. Am J Hematol. 1991 Jul;37(3):206-8
    1. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6585-9
    1. Am J Trop Med Hyg. 1991 Nov;45(5):593-601
    1. Diagn Microbiol Infect Dis. 1992 Feb;15(2):129-34
    1. J Protozool. 1991 Nov-Dec;38(6):223S-224S
    1. Biotech Histochem. 1992 May;67(3):140-8
    1. Blood. 1992 Aug 1;80(3):569-74
    1. Mol Aspects Med. 1992;13(2):113-65
    1. N Engl J Med. 1992 Nov 19;327(21):1473-7
    1. J Inorg Biochem. 1992 Aug 15-Sep;47(3-4):267-77
    1. N Engl J Med. 1992 Dec 24;327(26):1853-60
    1. Blood. 1993 Jan 1;81(1):214-21
    1. J Clin Invest. 1993 Jan;91(1):218-24
    1. Prog Med Chem. 1991;28:41-173
    1. Lancet. 1993 Apr 24;341(8852):1088-9

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere